Elanix Biotechnologies AG Logo

Elanix Biotechnologies AG

ISIN: DE000A0WMJQ4 | Ticker: ELN | LEI: 391200SYNFFL0NPAJK90

About Elanix Biotechnologies AG

Company Description

Elanix Biotechnologies is a tissue regeneration company. We develop and commercialize products for acute wound care, dermatological and gynecological applications, as well as providing cell technology services.

The company was founded in 2012 as a spin-off from the University Hospital of Lausanne (CHUV), Switzerland, to commercialize a patented progenitor cell technology. Progenitor cells are fully differentiated yet immunologically neutral cells that are very potent inducers of tissue growth and healing. Elanix owns GMP certified Master and Working cell banks containing vast quantities of cells.
The Company is headquartered in Epalinges, Switzerland with offices in Hamburg and listed on the Frankfurt stock exchange under the symbol ELN.

Year founded


Served area



c/o Frankfurt Hanauer Landstraße BC GmbH / Hanauer Landstraße 291 B, 60314 Frankfurt – Germany

Filings & Publications

Shareholder information

Shares outstanding



Dec. 1, 2015

Designated Sponsor(s)

mwb fairtrade Wertpapierhandelbank AG

Stock exchange(s)

Frankfurt Stock Exchange



Subscribe to our newsletter and receive information about recent IPOs, news in the European capital market and more.